# Fulvestrant and the Keto Diet A 2025 preclinical paper gives this topic its main importance. In ER-positive breast-cancer liver-metastasis models, a **ketogenic diet** helped at first. That benefit weakened over time. Adding **fulvestrant** changed that pattern. The combination blocked a key metabolic escape route and produced much deeper metastatic control. {% hint style="warning" %} This is preclinical evidence. It does not prove the same effect in patients. {% endhint %} ### The main point The paper suggests a simple sequence. * **KD alone** can reduce metastatic burden for a while. * Tumour cells can adapt by increasing **OXCT1**, a ketone-use enzyme. * **Fulvestrant** prevented that OXCT1 upregulation in the ER-positive models studied. * **KD plus fulvestrant** looked much stronger than KD alone. ### Why KD alone was not enough The longer experiment ran for **8 weeks**. Liver metastasis burden fell significantly at **day 37** (`p=0.022`) and **day 44** (`p=0.035`). By **day 51**, the value had drifted to `p=0.080`. That does not mean KD stopped doing anything. It suggests the anti-metastatic effect weakened as the tumour adapted. The proposed escape route was **OXCT1** upregulation. OXCT1 helps cells use ketones as fuel. ### What the shorter studies added #### The earlier 4-week study Earlier work from the same group reported that **KD plus fulvestrant** very effectively eliminated metastases. **KD alone** did not achieve that endpoint. #### The 2-week mechanistic study The shorter window let researchers collect viable tumour tissue before the combination cleared too much disease. With **KD alone**, tumour cells still showed glucose-carbon incorporation into metabolites linked to: * the **TCA cycle** * **alanine metabolism** * the **aspartate-malate shuttle** With **KD plus fulvestrant**, that incorporation was shut down. Fulvestrant also prevented the OXCT1 increase seen with KD alone. ### Why fulvestrant may matter metabolically In the ER-positive setting studied here, the combination created a metabolic double-trap: 1. The ketogenic diet reduced glucose access. 2. Fulvestrant blocked the ketone escape route. That left metastatic cells with far fewer usable fuel options. This is the core reason the combination matters more than diet alone. ### What this does and does not mean This paper does **not** show that keto is useless. It shows that keto pressure may be temporary when tumour cells adapt. It also does **not** prove that every ER-positive patient should use a ketogenic diet. The evidence here is mechanistic and preclinical. What it does offer is a plausible explanation for three real-world questions: * why ketogenic benefit may fade over time * why fulvestrant response may depend partly on metabolic context * why liver-metastatic ER-positive disease may deserve more metabolic attention ### Open question: why not test ER-negative models? The paper focused on **ER-positive** disease and did not include ER-negative models. That leaves an obvious research gap. Some separate breast-cancer literature links higher **OXCT1** expression with more aggressive, ER-negative biology. That makes ER-negative testing biologically interesting. It does **not** mean fulvestrant should be assumed useful there. Fulvestrant is an estrogen-receptor degrader. The mechanism in this paper depends on the ER-positive context studied. ### Bottom line This study helps explain why a ketogenic strategy alone may lose force over time in ER-positive breast cancer. The tumour can adapt metabolically. In the models studied, fulvestrant blocked that adaptation. That is why **KD plus fulvestrant** looked much stronger than **KD alone**. ### Questions that came up in our group discussion #### 1. What makes fulvestrant different from other hormone therapies in this KD context? Fulvestrant is not an aromatase inhibitor. It is a **selective estrogen receptor degrader (SERD)**. Beyond degrading **ERα**, available preclinical literature suggests fulvestrant also affects mitochondrial function, disrupts parts of tumour metabolism, and may influence chromatin activity at ER-linked regions. In the KD studies, that meant fulvestrant not only blocked estrogen signalling but also prevented **OXCT1** upregulation and glucose-carbon utilisation in liver metastases. That created the metabolic double-hit when combined with carbohydrate restriction. Other endocrine drugs, such as aromatase inhibitors, do not yet have the same preclinical KD-combination evidence in this setting. #### 2. Could similar benefits occur with other SERDs like elacestrant (Orserdu) plus a ketogenic diet? Second-generation oral SERDs such as **elacestrant** also degrade **ERα** and can be effective in **ESR1-mutated**, endocrine-resistant ER-positive metastatic breast cancer. Preclinical and clinical data show elacestrant has strong anti-estrogenic activity and can overcome some ESR1-mediated resistance. We do not yet have KD-combination studies equivalent to the fulvestrant liver-metastasis work. It is biologically plausible that SERDs with overlapping mechanisms could also synergise with KD. That remains a hypothesis. It needs dedicated studies or carefully monitored N-of-1 use rather than being assumed interchangeable with fulvestrant. ### References Zuo Q, Yoo JY, Nelson ER, Sikora MJ, Riggins RB. Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden. *npj Breast Cancer*. 2025;11(1):1-13. ### Related pages * [Endocrine Therapy, Stable Disease, and Dormancy in ER-Positive Breast Cancer](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/endocrine-therapy-stable-disease-and-dormancy-in-er-positive-breast-cancer.md) * [Blood Biopsy Trial — Getting Ahead of Treatment Resistance](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/blood-biopsy-trial-getting-ahead-of-treatment-resistance.md) --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/fulvestrant-and-the-keto-diet.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.